suggesting room for future upside. Axsome's products, particularly AXS-05, are positioned favorably in the competitive landscape of CNS therapeutics. The drug's differentiated safety profile and ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $143.00. The company’s shares closed ...

Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ...

UBS analysts increased the price target on Axsome Therapeutics (NASDAQ:AXSM) shares to $133.00, up from the previous $105.00, while maintaining a Buy rating on the stock. The company, currently valued ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Axsome Therapeutics, Inc. (NASDAQ ... This article provides a comprehensive analysis of Axsome's current position, future prospects, and potential challenges in the competitive CNS drug market.

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth. AXS-07 for acute migraine ... In conclusion, Axsome Therapeutics presents a compelling investment case with its ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ ... or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

Short interest in Axsome Therapeutics Inc (NASDAQ:AXSM) decreased during the last reporting period, falling from 6.62M to 5.75M. This put 14.22% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...